ClinicalTrials.gg
CompletedNCT02694523Updated Jul 30, 2021Results posted

BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis

A Phase 3 interventional study of risankizumab and adalimumab in Psoriasis, sponsored by AbbVie. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-30.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
684
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing risankizumab in Psoriasis — 1 open to participants now, 2 under way, 1 of them phase 3. risankizumab · Psoriasis.

Enrollment
2nd of 30
684 · median 162
Started
2016
with 5 others
Phase 3
17 of 30
none open now
Registered
7th of 30
by date
Lead sponsor
24 of 30
AbbVie

Among the 30 studies testing risankizumab in Psoriasis, this one is the 2nd largest by enrollment, is one of 6 that started in 2016, is one of 17 in phase 3, and was the 7th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

1 of the 30 studies testing risankizumab in Psoriasis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About risankizumab

risankizumab: first FDA approval 2019 (SKYRIZI), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing risankizumab in Psoriasis, or all of them as a file.
02

Study summary

This is a randomized double blind, double dummy, active comparator controlled, parallel design study that is performed to assess the safety and efficacy of BI 655066/ABBV-066 (risankizumab) compared to adalimumab to support registration for the treatment of moderate to severe chronic plaque psoriasis in adult patients.

Read the detailed description

This study consists of 2 parts (Part A and Part B).

Part A:

  • Participants were randomized to receive either risankizumab or adalimumab.

Part B:

  • Participants who received risankizumab in Part A continued to receive risankizumab in Part B
  • Adalimumab nonresponders (\<PASI 50 at Week 16) switched to risankizumab in Part B;
  • Adalimumab responders (PASI 90 at Week 16) continued to received adalimumab in Part B;
  • Adalimumab inadequate responders (PASI 50 to \<PASI 90) were rerandomized to receive either risankizumab or adalimumab in Part B.
03

Conditions studied

  • Psoriasis

Keywords

  • Psoriasis
  • Skin Diseases
  • Skin Diseases, Papulosquamous
  • Adalimumab
  • Anti-Inflammatory Agents
  • ABBV-066
  • BI 655066
  • Risankizumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients. Women of * must be ready and able to use highly effective methods of per ICH M3(R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information.

    *Women of childbearing potential are defined as:

    • having experienced menarche and
    • not (12 months with no menses without an alternative medical cause) and
    • not permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral oophorectomy or bilateral salpingectomy).
  • Age ≥ 18 years at screening
  • Have a diagnosis of chronic plaque psoriasis (with or without psoriatic arthritis) for at least 6 months before the first administration of study drug. Duration of diagnosis may be reported by the patient.
  • Have stable moderate to severe chronic plaque psoriasis with or without psoriatic arthritis at both Screening and Baseline (Randomization):

    • Have an involved body surface area (BSA) ≥ 10% and
    • Have a Psoriasis Area and Severity Index (PASI) score ≥ 12 and
    • Have a static Physician Global Assessment (sPGA) score of ≥ 3.
  • Must be candidates for systemic therapy or phototherapy for psoriasis treatment, as assessed by the investigator
  • Must be candidates for treatment with adalimumab (Humira®) according to local label as confirmed by the investigator.
  • Signed and dated written prior to admission to the study in accordance with GCP and local legislation

Exclusion criteria

Exclusion criteria:

  • Patients with

    • non-plaque forms of psoriasis (including guttate, erythrodermic, or pustular)
    • current drug-induced psoriasis (including an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
    • active ongoing inflammatory diseases other than psoriasis that might confound trial evaluations according to investigator's judgment
  • Previous exposure to ABBV-066
  • Previous exposure to adalimumab (Humira®)
  • Currently enrolled in another study or less than 30 days or more from screening since completing another investigational drug or device study.
  • Use of any restricted medication or any drug considered likely to interfere with the safe conduct of the study.
  • Major surgery performed within 12 weeks prior to randomization or planned within 12 months after screening (e.g. hip replacement, removal aneurysm, stomach ligation).
  • Known chronic or relevant acute infections, such as active tuberculosis (TB), (HIV) or viral hepatitis; QuantiFERON® TB test or purified protein derivative (PPD) skin test will be performed according to local labelling for Humira®. If the result is positive, patients may participate in the study if further work up (according to local practice/guidelines) establishes conclusively that the patient has no evidence of active TB. If presence of latent TB is established, then treatment should have been initiated and maintained according to local country guidelines.
  • Any documented active or suspected or history of malignancy within 5 years prior to screening, except appropriately treated basal cell or squamous cell carcinoma of the skin or in situ carcinoma of uterine cervix.
  • Evidence of a current or previous disease, medical condition (including chronic alcohol or drug abuse) other than psoriasis, surgical procedure (i.e., organ transplant), medical examination finding (including vital signs and [ECG]), or laboratory value at the Screening Visit outside the reference range that in the opinion of the investigator is and would make the study participant unreliable to adhere to the protocol or to complete the trial, compromise the safety of the patient, or compromise the quality of the data.
  • History of allergy/ to a systemically administered biologic agent or its
  • Women who are pregnant, nursing, or who plan to become pregnant while in the trial
  • Previous enrolment in this trial
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
684 participants (actual)

Study arms

  • Active comparator
    Adalimumab (Part A)

    Participants randomized to receive double-blind (DB) adalimumab 80 mg by subcutaneous (SC) injection at Week 0, then 40 mg at Week 1 and every 2 weeks for 15 weeks (Part A).

    Biological: adalimumab · Drug: placebo for risankizumab

  • Experimental
    Risankizumab (Part A)

    Participants randomized to receive risankizumab at Weeks 0 and 4 (Part A).

    Drug: risankizumab · Biological: placebo for adalimumab

Interventions

  • Risankizumab administered by subcutaneous (SC) injection

    Also known as: BI 655066, ABBV-066, SKYRIZI

  • Biologicaladalimumab

    Adalimumab pre-filled syringe, administered by subcutaneous (SC) injection

    Also known as: Humira, ABT-D2E7

  • Drugplacebo for risankizumab

    Placebo risankizumab administered by subcutaneous (SC) injection

  • Biologicalplacebo for adalimumab

    Placebo for adalimumab pre-filled syringe, administered by subcutaneous (SC) injection

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16 (Part A)

    PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. Nonresponder imputation (NRI) was used for missing data.

    Time frame: Week 16

  2. Percentage of Participants Achieving Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear at Week 16 (Part A)

    The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean \>0, \<1.5; Mild (2) = mean ≥1.5, \<2.5; Moderate (3) = mean ≥2.5, \<3.5; and Severe (4) = mean ≥3.5. NRI was used for missing data.

    Time frame: Week 16

  3. Percentage of Participants Who Were Re-Randomized to Receive Either Adalimumab or Risankizumab in Part B Achieving PASI90 at Week 44 (Part B)

    PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. NRI was used for missing data.

    Time frame: Week 44

Secondary outcomes

  1. Percentage of Participants Achieving PASI75 at Week 16 (Part A)

    PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI75 is defined as at least a 75% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. NRI was used for missing data.

    Time frame: Week 16

  2. Percentage of Participants Achieving PASI100 at Week 16 (Part A)

    PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI100 is defined as a 100% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. NRI was used for missing data.

    Time frame: Week 16

  3. Percentage of Participants Who Were Rerandomized to Receive Either Adalimumab or Risankizumab in Part B Achieving PASI100 at Week 44 (Part B)

    PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI100 is defined as a 100% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. NRI was used for missing data.

    Time frame: Week 44

  4. Percentage of Participants Who Were ReRandomized to Receive Either Adalimumab or Risankizumab in Part B Achieving sPGA Score of Clear at Week 44 (Part B)

    The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean \>0, \<1.5; Mild (2) = mean ≥1.5, \<2.5; Moderate (3) = mean ≥2.5, \<3.5; and Severe (4) = mean ≥3.5. NRI was used for missing data.

    Time frame: Week 44

Other outcomes

  1. Percentage of Participants Who Were Rerandomized to Receive Either Adalimumab or Risankizumab in Part B Achieving sPGA Score of Clear or Almost Clear at Week 44 (Part B)

    The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean \>0, \<1.5; Mild (2) = mean ≥1.5, \<2.5; Moderate (3) = mean ≥2.5, \<3.5; and Severe (4) = mean ≥3.5. NRI was used for missing data.

    Time frame: Week 44

07

Results

Posted May 28, 2019

Participant flow

Part A
Participant flow — Part A
MilestoneAdalimumab (Part A)Risankizumab (Part A)Risankizumab/Risankizumab (Part B)Adalimumab/Adalimumab (Part B)Adalimumab/Risankizumab (Part B)Adalimumab/Rerandomized to Adalimumab (Part B)Adalimumab/Rerandomized to Risankizumab (Part B)
Started30430100000
Completed29129400000
Not completed13700000
Withdrew: Adverse event7300000
Withdrew: Protocol violation1000000
Withdrew: Lost to follow-up1200000
Withdrew: Withdrawal by subject3100000
Withdrew: Other1100000
Part B
Participant flow — Part B
MilestoneAdalimumab (Part A)Risankizumab (Part A)Risankizumab/Risankizumab (Part B)Adalimumab/Adalimumab (Part B)Adalimumab/Risankizumab (Part B)Adalimumab/Rerandomized to Adalimumab (Part B)Adalimumab/Rerandomized to Risankizumab (Part B)
Started00294144385653
Completed00274140345151
Not completed00204452
Withdrew: Adverse event0071120
Withdrew: Protocol violation0010000
Withdrew: Lost to follow-up0023201
Withdrew: Withdrawal by subject0090130
Withdrew: Other0010001

Outcome measures

PrimaryPercentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16 (Part A)

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. Nonresponder imputation (NRI) was used for missing data.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16 (Part A)
percentage of participantsAdalimumab (Part A)Risankizumab (Part A)
Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16 (Part A)47.472.4
Statistical analysis
  • Adalimumab (Part A) vs Risankizumab (Part A) · Cochran-Mantel-Haenszel · p = <0.001 · Difference in percentage of participants: 24.9 · 95% CI 17.5 to 32.4
PrimaryPercentage of Participants Achieving Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear at Week 16 (Part A)

The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean \>0, \<1.5; Mild (2) = mean ≥1.5, \<2.5; Moderate (3) = mean ≥2.5, \<3.5; and Severe (4) = mean ≥3.5. NRI was used for missing data.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear at Week 16 (Part A)
percentage of participantsAdalimumab (Part A)Risankizumab (Part A)
Percentage of Participants Achieving Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear at Week 16 (Part A)60.283.7
Statistical analysis
  • Adalimumab (Part A) vs Risankizumab (Part A) · Cochran-Mantel-Haenszel · p = <0.001 · Difference in percentage of participants: 23.3 · 95% CI 16.6 to 30.1
PrimaryPercentage of Participants Who Were Re-Randomized to Receive Either Adalimumab or Risankizumab in Part B Achieving PASI90 at Week 44 (Part B)

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. NRI was used for missing data.

Time frame:
Week 44
Reported as:
Number · percentage of participants
Percentage of Participants Who Were Re-Randomized to Receive Either Adalimumab or Risankizumab in Part B Achieving PASI90 at Week 44 (Part B)
percentage of participantsAdalimumab/Rerandomized to Adalimumab (Part B)Adalimumab/Rerandomized to Risankizumab (Part B)
Percentage of Participants Who Were Re-Randomized to Receive Either Adalimumab or Risankizumab in Part B Achieving PASI90 at Week 44 (Part B)21.466.0
Statistical analysis
  • Adalimumab/Rerandomized to Adalimumab (Part B) vs Adalimumab/Rerandomized to Risankizumab (Part B) · Cochran-Mantel-Haenszel · p = <0.001 · Difference in percentage of participants: 45.0 · 95% CI 28.9 to 61.1
SecondaryPercentage of Participants Achieving PASI75 at Week 16 (Part A)

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI75 is defined as at least a 75% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. NRI was used for missing data.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving PASI75 at Week 16 (Part A)
percentage of participantsAdalimumab (Part A)Risankizumab (Part A)
Percentage of Participants Achieving PASI75 at Week 16 (Part A)71.790.7
Statistical analysis
  • Adalimumab (Part A) vs Risankizumab (Part A) · Cochran-Mantel-Haenszel · p = <0.001 · Difference in percentage of participants: 18.9 · 95% CI 13.0 to 24.9
SecondaryPercentage of Participants Achieving PASI100 at Week 16 (Part A)

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI100 is defined as a 100% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. NRI was used for missing data.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving PASI100 at Week 16 (Part A)
percentage of participantsAdalimumab (Part A)Risankizumab (Part A)
Percentage of Participants Achieving PASI100 at Week 16 (Part A)23.039.9
Statistical analysis
  • Adalimumab (Part A) vs Risankizumab (Part A) · Cochran-Mantel-Haenszel · p = <0.001 · Difference in percentage of participants: 16.7 · 95% CI 9.5 to 23.9
SecondaryPercentage of Participants Who Were Rerandomized to Receive Either Adalimumab or Risankizumab in Part B Achieving PASI100 at Week 44 (Part B)

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI100 is defined as a 100% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. NRI was used for missing data.

Time frame:
Week 44
Reported as:
Number · percentage of participants
Percentage of Participants Who Were Rerandomized to Receive Either Adalimumab or Risankizumab in Part B Achieving PASI100 at Week 44 (Part B)
percentage of participantsAdalimumab/Rerandomized to Adalimumab (Part B)Adalimumab/Rerandomized to Risankizumab (Part B)
Percentage of Participants Who Were Rerandomized to Receive Either Adalimumab or Risankizumab in Part B Achieving PASI100 at Week 44 (Part B)7.139.6
Statistical analysis
  • Adalimumab/Rerandomized to Adalimumab (Part B) vs Adalimumab/Rerandomized to Risankizumab (Part B) · Cochran-Mantel-Haenszel · p = <0.001 · Difference in percentage of participants: 32.8 · 95% CI 18.8 to 46.9
SecondaryPercentage of Participants Who Were ReRandomized to Receive Either Adalimumab or Risankizumab in Part B Achieving sPGA Score of Clear at Week 44 (Part B)

The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean \>0, \<1.5; Mild (2) = mean ≥1.5, \<2.5; Moderate (3) = mean ≥2.5, \<3.5; and Severe (4) = mean ≥3.5. NRI was used for missing data.

Time frame:
Week 44
Reported as:
Number · percentage of participants
Percentage of Participants Who Were ReRandomized to Receive Either Adalimumab or Risankizumab in Part B Achieving sPGA Score of Clear at Week 44 (Part B)
percentage of participantsAdalimumab/Rerandomized to Adalimumab (Part B)Adalimumab/Rerandomized to Risankizumab (Part B)
Percentage of Participants Who Were ReRandomized to Receive Either Adalimumab or Risankizumab in Part B Achieving sPGA Score of Clear at Week 44 (Part B)7.139.6
Statistical analysis
  • Adalimumab/Rerandomized to Adalimumab (Part B) vs Adalimumab/Rerandomized to Risankizumab (Part B) · Cochran-Mantel-Haenszel · p = <0.001 · Difference in percentage of participants: 32.8 · 95% CI 18.8 to 46.9
Other pre-specifiedPercentage of Participants Who Were Rerandomized to Receive Either Adalimumab or Risankizumab in Part B Achieving sPGA Score of Clear or Almost Clear at Week 44 (Part B)

The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean \>0, \<1.5; Mild (2) = mean ≥1.5, \<2.5; Moderate (3) = mean ≥2.5, \<3.5; and Severe (4) = mean ≥3.5. NRI was used for missing data.

Time frame:
Week 44
Reported as:
Number · percentage of participants
Percentage of Participants Who Were Rerandomized to Receive Either Adalimumab or Risankizumab in Part B Achieving sPGA Score of Clear or Almost Clear at Week 44 (Part B)
percentage of participantsAdalimumab/Rerandomized to Adalimumab (Part B)Adalimumab/Rerandomized to Risankizumab (Part B)
Percentage of Participants Who Were Rerandomized to Receive Either Adalimumab or Risankizumab in Part B Achieving sPGA Score of Clear or Almost Clear at Week 44 (Part B)33.973.6
Statistical analysis
  • Adalimumab/Rerandomized to Adalimumab (Part B) vs Adalimumab/Rerandomized to Risankizumab (Part B) · Cochran-Mantel-Haenszel · p = <0.001 · Difference in percentage of participants: 38.9 · 95% CI 22.0 to 55.8

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from first dose of study drug until 15 weeks after the last dose of study drug (up to 48 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adalimumab (Part A)2/304 (0.7%)9/304 (3%)71/304 (23.4%)
Risankizumab (Part A)1/301 (0.3%)10/301 (3.3%)76/301 (25.2%)
Risankizumab/Risankizumab (Part B)0/294 (0%)12/294 (4.1%)95/294 (32.3%)
Adalimumab/Risankizumab (Part B)0/38 (0%)4/38 (10.5%)16/38 (42.1%)
Adalimumab/Rerandomized to Adalimumab (Part B)0/56 (0%)2/56 (3.6%)21/56 (37.5%)
Adalimumab/Rerandomized to Risankizumab (Part B)0/53 (0%)3/53 (5.7%)24/53 (45.3%)
Most frequent serious events
Showing 10 of 46
Most frequent serious events
EventAdalimumab (Part A)Risankizumab (Part A)Risankizumab/Risankizumab (Part B)Adalimumab/Risankizumab (Part B)Adalimumab/Rerandomized to Adalimumab (Part B)Adalimumab/Rerandomized to Risankizumab (Part B)
ErysipelasInfections and infestations0/3040/3010/2942/380/560/53
Coronary artery occlusionCardiac disorders0/3040/3010/2941/380/560/53
Abdominal painGastrointestinal disorders1/3040/3010/2941/380/560/53
PneumoniaInfections and infestations0/3040/3011/2941/380/560/53
SepsisInfections and infestations1/3040/3011/2941/380/560/53
Anticoagulation drug level above therapeuticInvestigations0/3040/3010/2941/380/560/53
Alcohol withdrawal syndromePsychiatric disorders0/3040/3010/2941/380/560/53
InfluenzaInfections and infestations0/3040/3010/2940/380/561/53
Urinary tract infectionInfections and infestations0/3040/3011/2940/380/561/53
Joint dislocationInjury, poisoning and procedural complications0/3040/3010/2940/380/561/53
Most frequent other events
Most frequent other events
EventAdalimumab (Part A)Risankizumab (Part A)Risankizumab/Risankizumab (Part B)Adalimumab/Risankizumab (Part B)Adalimumab/Rerandomized to Adalimumab (Part B)Adalimumab/Rerandomized to Risankizumab (Part B)
Viral upper respiratory tract infectionInfections and infestations24/30426/30139/2949/387/5614/53
Upper respiratory tract infectionInfections and infestations12/30421/30134/2943/385/564/53
HypertensionVascular disorders8/3041/3019/2943/381/561/53
HeadacheNervous system disorders20/30412/3016/2942/383/563/53
BronchitisInfections and infestations3/3044/3017/2942/383/562/53
ArthralgiaMusculoskeletal and connective tissue disorders9/30411/3014/2940/383/562/53
Back painMusculoskeletal and connective tissue disorders6/3049/3016/2940/383/562/53
Seborrhoeic keratosisNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3040/3012/2942/380/560/53
Oropharyngeal painRespiratory, thoracic and mediastinal disorders3/3046/3013/2942/381/562/53

Baseline characteristics

Intent-to-treat population in Part A (ITT_A): All subjects randomized at Baseline.

Age, Continuous
Age, Continuous(years)Adalimumab (Part A)Risankizumab (Part A)Total
Mean47.0 ± 13.0945.3 ± 13.7946.2 ± 13.46
Sex: Female, Male
Sex: Female, Male(Participants)Adalimumab (Part A)Risankizumab (Part A)Total
Female9291183
Male212210422
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Adalimumab (Part A)Risankizumab (Part A)Total
Hispanic or Latino5944103
Not Hispanic or Latino245257502
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Adalimumab (Part A)Risankizumab (Part A)Total
American Indian or Alaska Native022
Asian354176
Native Hawaiian or Other Pacific Islander000
Black or African American61117
White263245508
More than one race022
Unknown or Not Reported000
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Reich K, Gooderham M, Thaci D, Crowley JJ, Ryan C, Krueger JG, Tsai TF, Flack M, Gu Y, Williams DA, Thompson EHZ, Paul C. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet. 2019 Aug 17;394(10198):576-586. doi: 10.1016/S0140-6736(19)30952-3. Epub 2019 Jul 4. Erratum In: Lancet. 2019 Aug 17;394(10198):564. doi: 10.1016/S0140-6736(19)31664-2. PubMed 31280967 ↗
  • Lebwohl MG, Soliman AM, Yang H, Wang J, Hagan K, Padilla B, Pinter A. Impact of Risankizumab on PASI90 and DLQI0/1 Duration in Moderate-to-Severe Psoriasis: A Post Hoc Analysis of Four Phase 3 Clinical Trials. Dermatol Ther (Heidelb). 2022 Feb;12(2):407-418. doi: 10.1007/s13555-021-00660-3. Epub 2021 Dec 18. PubMed 34921669 ↗
  • Suleiman AA, Khatri A, Oberoi RK, Othman AA. Exposure-Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis. Clin Pharmacokinet. 2020 May;59(5):575-589. doi: 10.1007/s40262-019-00829-2. PubMed 31667790 ↗
  • Suleiman AA, Minocha M, Khatri A, Pang Y, Othman AA. Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I-III Clinical Trials. Clin Pharmacokinet. 2019 Oct;58(10):1309-1321. doi: 10.1007/s40262-019-00759-z. PubMed 31054118 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2016 to primary completion in Aug 2017, 17 months.

Results were first posted in May 2019, 1 year 9 months after primary completion. A results delay was requested in Jan 2018.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 17 months is above that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2016
First posted
Feb 29, 2016
StartActual
Mar 2016
Primary completionActual
Aug 2017
CompletionActual
Aug 2017
Results delay requested
Jan 9, 2018
Results first posted
May 28, 2019
Last update
Jul 30, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02694523
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Feb 29, 2016
Start date
Mar 2016
Primary completion
Aug 2017
Completion
Aug 2017
Results posted
May 28, 2019
Last update
Jul 30, 2021

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risankizumab

Start the discussion